{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:36:20Z","timestamp":1782513380671,"version":"3.54.5"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.clon.2016.09.004","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T03:16:59Z","timestamp":1476674219000},"page":"e13-e28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline"],"prefix":"10.1016","volume":"29","author":[{"given":"A.","family":"Prica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-9371","authenticated-orcid":false,"given":"F.","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.K.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kouroukis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2016.09.004_bib1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib2","first-page":"228","article-title":"Use of rituximab in the treatment of lymphoma: an evidence summary","volume":"6","author":"Imrie","year":"1999","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib3","series-title":"Review Manager (RevMan) [Computer program]","year":"2012"},{"key":"10.1016\/j.clon.2016.09.004_bib4","first-page":"194","article-title":"Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial","volume":"22","author":"Aviles","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.clon.2016.09.004_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02685907","article-title":"Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma","volume":"24","author":"Aviles","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib6","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib7","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mds600","article-title":"Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)","volume":"24","author":"Ketterer","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"High-grade non-Hodgkin lymphoma study, six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib11","first-page":"300","article-title":"Final analysis of a randomized, phase III, trial using etoposide and G-CSF with or without rituximab (R) for peripheral stem cell mobilization (PSC) in B-cell non-Hodgkin lymphoma (B-NHL)","author":"Pohlman","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib12","first-page":"685","article-title":"Addition of rituximab improves outcome of HIV negative patients with Burkitt lymphoma treated with the Lmba protocol: results of the randomized intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR sponsored LMBA02, NCT00180882)","author":"Ribrag","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib13","first-page":"210","article-title":"Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell non-Hodgkin's lymphoma in elderly patients","author":"Sonneveld","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib14","first-page":"118","article-title":"Integration of rituximab and liposomal doxorubicin (DOXIL) into CODOX-M\/IVAC for HIV-negative and HIV+ adults with untreated Burkitt's lymphoma (BL): results of a prospective multicenter phase II study","volume":"21","author":"Evens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib15","first-page":"667","article-title":"Substantially improved outcome of adult Burkitt non-Hodgkin lymphoma and leukemia patients with rituximab and a short-intensive chemotherapy. Report of a large prospective multicenter trial","author":"Hoelzer","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/10428194.2012.715346","article-title":"Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma\/leukemia","volume":"54","author":"Kasamon","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clon.2016.09.004_bib17","first-page":"116","article-title":"Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for burkitt or burkitt-like leukemia\/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002","volume":"21","author":"Rizzieri","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2016.09.004_bib19","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","article-title":"Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group","volume":"24","author":"Wasterlid","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CLML.2010.n.017","article-title":"ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma","volume":"10","author":"Aviles","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clon.2016.09.004_bib21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","article-title":"Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial","volume":"111","author":"Vellenga","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib22","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib23","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdp237","article-title":"Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma","volume":"20","author":"Haioun","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib24","first-page":"118","article-title":"Rituximab maintenance therapy in diffuse large B-cell lymphoma in a multicenter prospective randomised phase II study","volume":"21","author":"Witzens-Harig","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib25","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib26","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma","volume":"24","author":"Boue","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib27","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","article-title":"Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial","volume":"140","author":"Ribera","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clon.2016.09.004_bib29","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials","volume":"105","author":"Spina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib32","first-page":"2431","article-title":"Is first line single agent Rituximab the best treatment for indolent non-Hodgkin's lymphoma? Update of a multicentric study comparing Rituximab vs CNOP vs Rituximab plus CNOP","author":"Rivas-Vera","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib33","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib34","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib35","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib36","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib37","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10428190802688509","article-title":"Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study","volume":"50","author":"Eve","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clon.2016.09.004_bib39","first-page":"8000","article-title":"Alliance for Clinical Trials in Oncology, CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma","volume":"30","author":"Leonard","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib40","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib41","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib42","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib43","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib44","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib45","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712","volume":"29","author":"Woyach","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib46","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2011-07-365437","article-title":"Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial","volume":"119","author":"Lepretre","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib47","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2016.09.004_bib48","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2141.2010.08317.x","article-title":"A\u00a0randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia","volume":"152","author":"Hillmen","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clon.2016.09.004_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","article-title":"Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis","volume":"57","author":"Dong","year":"2013","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.clon.2016.09.004_bib51","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib52","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib53","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib54","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib55","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib56","first-page":"3049","article-title":"The addition of Rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial","author":"Hoster","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib57","first-page":"6","article-title":"An intergroup randomised trial of Rituximab versus a watch and wait strategy In patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis","author":"Ardeshna","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib60","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss group for clinical cancer research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib61","article-title":"Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35\/98","volume":"27","author":"Ghielmini","year":"2009","journal-title":"J Clin Oncol Conf"},{"key":"10.1016\/j.clon.2016.09.004_bib62","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib63","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","volume":"31","author":"Vitolo","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib64","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib65","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma \u2013 a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib66","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib67","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib68","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2016.09.004_bib69","first-page":"1236","article-title":"Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation","volume":"90","author":"Barosi","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clon.2016.09.004_bib70","first-page":"7502","volume":"24","author":"Dreyling","year":"2006","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib71","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2016.09.004_bib72","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2016.09.004_bib73","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.09.004_bib74","first-page":"6528","article-title":"Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","author":"Dreyling","year":"2005","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.clon.2016.09.004_bib75","first-page":"7004","article-title":"Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial","author":"Goede","year":"2013","journal-title":"ASCO Meeting Abstracts"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516302874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516302874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:43:13Z","timestamp":1760542993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655516302874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0936655516302874"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2016.09.004","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2016.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}